Continuing Cardiology Education
|
|
- Gervais Riley
- 5 years ago
- Views:
Transcription
1 Continuing Cardiology Education REVIEW ARTICLE Risk stratification for the primary prevention of arrhythmic sudden cardiac death in post-infarction patients Part II: Cardiac magnetic resonance and electrophysiological study. Trials connecting the risk stratification approaches with the ICDs. The unexplored new eras of the stable patients with preserved ejection fraction and the patients within the early post-myocardial infarction period P. Arsenos*, S. Sideris & K. A. Gatzoulis Electrophysiology Laboratory & First Divison of Cardiology, Medical School, National and Kapodistrian, University of Athens, Athens, Greece Keywords Myocardial infarction, risk stratification, sudden cardiac death Correspondence Petros Arsenos, Athinon-Chalkidos 26, Avlonas Attikis, P.O. Box 19011, Greece. Tel/ Fax: ; Funding Information No Funding information provided. Continuing Cardiology Education, 2016; 2(3), doi: /cce2.33 Abstract Current trends on Sudden Cardiac Death (SCD) Risk Stratification complementary to the conventional markers that were presented in Part I, are Cardiac Magnetic Resonance that detects and quantifies the post-infarct tissue heterogeneity and the invasive method of Programmed Ventricular Stimulation on Electrophysiological study that reveals the vulnerable and inducible myocardial substrate. While the first generation of Risk Stratification trials examined one simple prognostic marker each time, the second generation of trials investigated in past combinations of SCD prediction markers and prognostic models reflecting different arrhythmogenesis mechanisms. The third generation of trials currently utilizes Risk Stratification strategies to indentify high-risk patients before an ICD prophylactic implantation connecting the Risk Stratification process with the ICD therapy. Intensive research on SCD is also nowadays directed to the unexplored era of patients with a Preserved Ejection Fraction and to the era of early post-myocardial infarction period. Both these subgroup patients are not protected by the current ICDs implantation guidelines because of gap in evidence. Research is going to fill in this gap. Answer questions and earn CME: /Activity.aspx Cardiac Magnetic Resonance Post-infarct fibrosis plays an important role in the arrhythmogenic myocardial architecture promoting reentrant excitation [1, 2]. Quantification of the peri-infarct zone with Myocardial Delay Enhancement during Cardiac Magnetic Resonance Imaging (CMR) in 144 patients proved a predictor of cardiovascular mortality independently from age and LVEF during a median follow up of 2.4 years [3]. Tissue heterogeneity at the infarct periphery was strongly associated with inducibility for monomorphic VT during electrophysiological or device testing [4] and the infarct gray zone as a measure of tissue heterogeneity predicted appropriate ICD activations in post-myocardial infarction patients [5, 6]. In an experimental animal model, the MRI heterogeneous zone of normal myocardial tissue mixed with post-infarct scar found to contain the critical isthmuses for ventricular tachycardia[7] while post-infarction VT-related slow conduction channels indentified by CMR in VT patients are found to correspond in location and orientation well with Endocardial Voltage Mapping indentified slow conduction channels [8]. In reverse 235 ischemic and non-ischemic patients with LVEF 35% and an ICD with small heterogeneous myocardial tissue values within the lowest tertile were at low arrhythmic risk with only a 0.7% year event rate [9]. Continuing Cardiology Education, doi: /cce2.33 (144 of 150)
2 P. Arsenos et al. Risk Stratification for Sudden Cardiac Death in Post-infarction Patients Vulnerability in Electrophysiological Testing As the myocardial infarction heals a scar remains. This fibrotic area constitutes the anatomical substrate for the initiation and maintenance of an electrical re-entry circuit that may establish a dangerous VT. Programmed ventricular stimulation evaluates the arrhythmia inducibility in the electrophysiology laboratory [10] (Figure 1). The performance of electrophysiological testing (EPT) depends on the stimulation protocol used (number and degree of prematurity of programmed extra stimuli) as well as the sites of stimulation and the underlying severity of left ventricular dysfunction, and/or the other previously mentioned non-invasive high-risk indices of an abnormal substrate and repolarization phase [10]. The value of EPT in the risk stratification process has been well documented by previous studies [11 15]. EPT was used successfully to select patients for ICD implantation in the MADIT I [16] and MUSTT [17] trials, whereas a MADIT II subanalysis reported that EPT predicted VT but not VF [18]. Following this report, the value of the method for risk stratification of the post-mi patient was partly questioned. Regardless of this, EPT is a powerful prognostic tool for the assessment of high-risk patients [19], and this has been further confirmed by recent studies [13 15]. ICDs establishment by the First Generation risk stratification studies enrolling patients based on low LVEFs and fundamental risk stratification markers Twenty years ago, it was known that the lower the LVEF, the higher the arrhythmic risk, and during that period LVEF was the main risk stratifier that could fast and efficiently discriminate the high from the low arrhythmic risk patients. For this reason, LVEF was selected as an enrollment criterion for the first trials testing the ICDs in clinical conditions. Multicenter Automatic Defibrillator Trial (MADIT I) demonstrated that ICDs reduced mortality by nearly half compared with medical therapy alone, in post- MI patients with heart failure and depressed LVEF 35% along with non-sustained VT (NSVT), and non-suppressible by procainamide sustained ventricular tachyarrhythmia on electrophysiological study (EPS) [16]. A similar in design and results study was the MUSTT which randomized post-mi patients with NSVT, LVEF 40% and inducible sustained ventricular tachyarrhythmias on EPS into an ICD versus an EP-guided conventional antiarrhythmic drug therapy approach [17]. The next study, MADIT II, randomized patients with prior MI and LVEF 30% to medical therapy or ICD implantation and announced a significant 31% reduction in the risk of death with ICD implantation [20]. A fourth one, the Sudden Cardiac Figure 1. Programmed Ventricular Stimulation in a 76-year-old post-mi patient with monomorphic sustained ventricular tachycardia induction. The patient received an ICD. APRET database NCT: Continuing Cardiology Education, doi: /cce2.33 (145 of 150)
3 Risk Stratification for Sudden Cardiac Death in Post-infarction Patients P. Arsenos et al. Death in Heart Failure Trial (SCD-HeFT), randomized 2521 ischemic and non-ischemic cardiomyopathy patients with congestive heart failure (LVEF 35%) and demonstrated a significant 23% reduction in mortality in ICD recipients compared with control patients treated with amiodarone [21]. All four studies demonstrated a significant ICD survival benefit based on a risk stratification approach of a low LVEF as far as the primary prevention of SCD. The device s benefit directly connected with the risk stratifier and in this way both the ICDs and the LVEF were incorporated into the Guidelines and a non-arrhythmic entity, the left ventricular systolic dysfunction, became the main approved arrhythmic risk stratifier for the post-mi and dilated cardiomyopathy patients selection for an ICD implantation for primary prevention of SCD during the last decade. Once again these studies demonstrated a significant ICD survival benefit based on a risk stratification approach related to a low LVEF, a policy with several limitations when considering the epidemiologic aspect of SCD. The Second Generation Studies Combining Non-invasive tests for SCD Prediction During the lasts 15 years, several studies explored the performance of combined non-invasive tests for SCD prediction (Table 1). Ikeda in 2000 combined the left ventricular systolic dysfunction (LVEF) with a depolarization abnormality marker (SAECG late potentials) and a repolarization abnormality marker (TWA) in 102 post-mi patients. The highest positive predictive value (50%) was obtained when TWA and LP were combined [22]. Exner, in 2007 in the REFINE study combined a LVEF <0.50 with the autonomic tone marker of heart rate turbulence (HRT) and the electrical substrate marker of T-wave alternans (TWA) which were assessed in two different post-mi periods (2 4 weeks versus weeks after MI). An impaired HRT with abnormal TWA, and an EF <0.50 detected by the later testing beyond 8 weeks after MI, identified patients at risk of serious events [23]. Huikuri in the CARISMA study in 2009 found that the reduced very low frequency component of heart rate variability and the induction of sustained monomorphic VT during EPS were predicting the primary endpoint of an ECG-documented ventricular fibrillation or symptomatic sustained ventricular tachycardia (VT) [14]. A New Era: SCD in Patients with Preserved Ejection Fraction Ventricular tachyarrhythmias in patients with preserved left ventricular systolic function are less common to occur in comparison to those patients with a reduced LVEF. Although the risk for SCD is lower in these patients, it is not negligible and in one post-mi cohort is estimated to be 0.6% per year [24]. Ikeda in 2006 was the first investigator trying to explore SCD prediction in preserved LVEFs by screenning post- MI patients with LVEF >40% (average 55 10%) with TWA, NSVT and SAECG Late Potentials. On multivariate analysis, a positive microvolt TWA test was the most significant predictor, with a hazard ratio of 19.7 (P < ) [24]. It is interesting that all three arrhythmia-related non-invasive indices were associated with a rather significant incidence of arrhyhtmic events. Bauer in the ISAR-Risk study in 2009 investigated HRT and DC combined. Patients found with both these autonomic function indices affected were considered suffering from severe autonomic failure (SAF). An important finding of the study was that among 2223 patients with LVEF Table 1. Studies combining non-invasive tests for SCD prediction. Study Population Tests End point Event rate Performance PPV NPV Ikeda, 2000 [22] REFINE, 2007 [23] CARISMA,2009 [14] Ikeda, 2006 [24] ISAR-R, 2009 [25] n = 102, LVEF=49% LVEF, LPs,TWA VT/VF 15% (13.8% py) n = 322,LVEF<0.50% LVEF,HRT,TWA CD/CA 11.5% (2.9% py) n = 312, LVEF=31% HRV/T,AR,LPs, VT/VF (ILR) 8% TWA,EPS (4% py) n = 1.003,LVEF>40% TWA,NSVT,LPs SCD,CA,VF 1.8% LVEF=55% (0.6% py) n = 2223, LVEF>30% HRT+DC Total Mortality 6.4% (1.3% py) HR:8.6 50% 92% HR: % 95% (VLF) HR:7 26% 95% (EPS) HR:4.8 23% 96% (TWA)HR:19.7 9% 99% HR:4.6 38% 94% LVEF, Left ventricular ejection fraction; LPs, Late Potentials; TWA, T wave alternans; HRT, heart rate turbulence; HRV, heart rate variability; AR, arrhythmias; EPS, electrophysiological study; NSVT, non-sustained ventricular tachycardia; DC, deceleration capacity of heart rate; VT, ventricular tachycardia; VF, ventricular fibrillation; CD, cardiac death; CA, cardiac arrest; ILR, implantable loop recorder; SCD, sudden cardiac death; HR, hazard ratio; VLF, very low frequencies from heart rate variability; PPV, positive predictive value; NPV, negative predictive value. Continuing Cardiology Education, doi: /cce2.33 (146 of 150)
4 P. Arsenos et al. Risk Stratification for Sudden Cardiac Death in Post-infarction Patients >30%, SAF identified another high-risk group of 117 patients with 37 deaths [25]. These trials confirmed that SCD could be predicted by different methods even among post-mi patients with preserved LVEF. The Early Post- myocardial Infarction Period Paradoxically although epidemiological data indicate an increased arrhythmic mortality early after a Myocardial Infarction, the previous two clinical trials specifically designed for investigating this issue, IRIS [26] and DYNAMIT [27], both concluded that prophylactic ICD therapy did not reduce overall mortality among high-risk patients with a recent acute myocardial infarction. As a consequence, current Guidelines based on these two trials do not recommend an early ICD implantation after myocardial infarction (classiii, Level of Evidence A) [28]. IRIS included patients with a reduced LVEF<40% and an elevated Heart rate > 90 bpm and/or NSVT while the mean LVEF was 34.6% for the ICD group. The death rates were as high as 10.6% at 1 year, a rather high event rate. DYNAMIT included post-mi patients with a depressed LVEF 35% and a depressed SDNN/HRV <70 msec or an elevated Heart rate >80 bpm. The mean LVEF in ICD group was as low as 28% while the mean SDNN was severely impaired at 61 msec, despite optimal medical therapy. The annual mortality rate in ICD group was 7.5%. Both these studies were based on LVEF and Autonomic Nervous System indices rather pointing to pump failure mortality candidates than to the arrhythmic mortality ones. Their findings were in accordance with their design, and it is clear that both these trials failed to select the arrhythmia vulnerable patients. Unfortunately the risk of SCD is highest early following MI, with a rate 6 times higher in the first month than after 1 year. The role of an electrophysiologically guided approach by performing Ventricular stimulation in all post-mi patients with a LVEF 40% before hospital discharge is promising [11 15]. This strategy is currently under prospective randomized controlled fashion investigation in the PRO- TECT-ICD study [29]. The Current status: Third Generation Studies applying Risk Stratification Strategies to Indentify High Risk Patients Most Likely to Benefit from ICD Prophylactic Implantation Research status on the field currently include trials that utilize risk stratification approaches for the selection of patients for prophylactic ICD implantation or trials that randomize patients to prove that patients identified as being at risk with the techniques used derive benefit from an ICD. Some of them are referring to post-mi patients with relatively well maintained left ventricular systolic function, a group of patients not studied in previous trials (Table 2). The efficacy of implantable defibrillator therapy after a myocardial infarction trial (REFINE-ICD/NCT ) It consists of the next step of the previous REFINE trial. It recruits post-mi patients with LVEF since The patients with abnormal HRT and abnormal TWA measured in Holter recordings were randomized to ICD or to Conventional therapy group [30]. Results are expected. Table 2. Current studies applying a Risk Stratification-guided ICD prophylactic therapy. Study Population Tests Randomization/ Intervention End point Status Reference REFINE-ICD ( ) CMR GUIDE ( ) PRESERVE EF ( ) PROTECT ICD ( ) n = 1400 LVEF: 36 50% n = 428 LVEF: 36 50% n = 1000 LVEF>40% n = 1058 LVEF 40% HRT/TWA ICD vs Control TM Recruiting NCT [30] LGE on CMR ICD vs ILR SCD and VT Recruiting NCT [31] NIRS+EPS No randomization SCD,VT,ICD Recruiting NCT ICD after EPS activation [32, 33] EPS 2-40 days Post-MI ICD vs Control CA,VT,VF,SCD Recruiting ACTRN [29] LVEF, left ventricular ejection fraction; HRT, heart rate turbulence; TWA, T wave alternans; LGE, late gadolinium enhancement; CMR, cardiac magnetic resonance; NIRS, non-invasive risk stratification; EPS, electrophysiological study; ICD, implantable cardiac defibrillator; ILR, implantable loop recorder; TM, total mortality; SCD, sudden cardiac death; VT, ventricular tachycardia; CA, cardiac arrest; VF, ventricular fibrillation. Continuing Cardiology Education, doi: /cce2.33 (147 of 150)
5 Risk Stratification for Sudden Cardiac Death in Post-infarction Patients P. Arsenos et al. The cardiac magnetic resonance-guided management of mild to moderate left ventricular systolic dysfunction trial. (CMR GUIDE/NCT ) A multicentre randomized controlled trial in which 428 patients with mild to moderate left ventricular systolic dysfunction (either ICM or NICM) and ventricular scar/ fibrosis on cardiovascular magnetic resonance are randomized to either ICD or implantable loop recorder (ILR) insertion and are followed up for 3 years. The primary hypothesis is that among patients with mild to moderate left ventricular systolic dysfunction, a routine CMR-guided management strategy of ICD insertion is superior to a conservative strategy of standard care [31]. The Risk Stratification in Patients With Preserved Ejection Fraction trial (PRESERVE EF/NCT ) This observational and interventional study is currently selecting asymptomatic post-mi patients late after MI (40 days after STEMI and N-STEMI) with preserved ejection fraction (LVEF 40%) and absence of active ischemia evaluating their arrhythmic risk based on a combined two steps non-invasive and Invasive approach. The first step is based on multiple Non-invasive markers evaluation. Patients found at risk are subsequently undergoing programmed ventricular stimulation. Inducible patients receive an ICD with the hypothesis of an appropriate device activation during follow up and improved survival [32, 33]. The Programmed ventricular stimulation to risk stratify for early cardioverterdefibrillator (ICD) implantation to prevent tachyarrhythmias following acute myocardial infarction trial. (PROTECT-ICD/ ACTRN ) Focusing on the early (2 40 days) post-mi period, this study selects the patients with a depressed LVEF 40% for an electrophysiologically study-guided early prophylactic ICD implantation (first 40 days) for primary prevention of SCD [29]. Future Trends on Risk Stratification Innovative research is evolving in the field of complex cardiac, respiratory and brain bio-signals. Open signal databases and downloadable programs facilitate international interdisciplinary research. Such important e-sites and groups include: (1) Physionet with the MIT-BIH Arrhythmia Database ( (2) The Working Group of Biological SignalAnalyses of TUM ( (3) The AcademicWorking Group of Eberhard-Karls-Universit at T ubingen ( (4) The Working Group on in e-cardiology of the European Society of Cardiology ( (5) The International Scientific Conference, Computing in Cardiology ( (6) The International Society of Holter and Non-invasive Electrocardiology ( Relevant to the daily clinical practice, the evolution of technology made possible all the noninvasive markers to be incorporated into the Holter software. Risk stratification has been simplified. Collection and analysis of massive prognostic information from just a simple daily heart signal recording during hospitalization, or in out-patient clinics or even in the private cardiology office consist already a daily routine. Innovative technology and research on Holter enforced doctors, providing them with the tools for protecting their patients. This first non-invasive screening is possible to be completed by a cardiologist even in a private external cardiology office and the patients found under risk to be referred for EPS and/or CMR further evaluation. Conflict of Interest All authors have nothing to disclose. References 1. Peters, NS, and AL Wit Myocardial architecture and ventricular arrhythmogenesis. Circulation 97: Bakker, JM, F Capelle, MJ Janse et al Reentry as a cause of ventricular tachycardia in patients with chronic ischemic heart disease:electrophysiologic and anatomic correlation. Circulation 77: Yan, TA, AJ Shayne, KA Brown et al Characterization of the peri-infarct zone by contrastenhanced cardiac magnetic resonance imaging is a powerfull predictor of post- myocardial infarction mortality. Circulation 114: Schmidt, A, CF Azevedo, A Cheng et al Infarct tissue heterogeneity by magnetic resonance imaging identifies enhanced cardiac arrhythmia susceptibility in patients with left ventricular dysfunction. Circulation 115: Roes, SD, JW Borleffs, RJ van der Geest et al Infarct tissue heterogeneity assessed with contrast-enhanced mri predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardiovberter-defibrillator. Circ. Cardiovasc. Imaging 2: Continuing Cardiology Education, doi: /cce2.33 (148 of 150)
6 P. Arsenos et al. Risk Stratification for Sudden Cardiac Death in Post-infarction Patients 6. Boye, P, H Abdel-Aty, U Zacharzowsky et al Prediction of life-threatening arrhythmic events in patients with chronic myocardial infarction by contrast-enhanced CMR. J. Am. Coll. Cardiol. Img. 4: Estner, HL, MM Zviman, D Herzka et al The critical isthmus sites of ischemic ventricular tachycardia are in zones of tissue heterogeneity, visualized by magnetic resonance imaging. Heart Rhythm 8: Perez-David, E, A Arenal, JL Rubio-Guivernau et al Noninvasive identification of ventricular tachycardiarelated conducting channels using contrast-enhanced magnetic resonance imaging in patients with chronic myocardial infarction: comparison of signal intensity scar mapping and endocardial voltage mapping. J. Am. Coll. Cardiol. 57: Wu, KC, G Gerstenblith, E Guallar et al Combined cardiac magnetic resonance imaging and c-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ. Cardiovasc. Imaging 5: Arsenos, P, K Gatzoulis, P Dilaveris et al Arrhythmic sudden cardiac death: substrate, mechanisms and current risk stratification strategies for the postmyocardial infarction patient. Hellenic J. Cardiol. 54: Buxton, AE, FE Marchlinski, BT Flores et al Nonsustained ventricular tachycardia in patients with coronary artery disease: role of electrophysiologic study. Circulation 75: Zaman, S, A Narayan, A Thiagalingam et al Long term arrhythmia-free survival in patients with severe left ventricular dysfunction and no inducible ventricular tachycardia after myocardial infarction. Circulation 129 (8): De Ferrari, GM, R Rordorf, F Frattini et al Predictive value of programmed ventricular stimulation in patients with ischaemic cardiomyopathy: implications for the selection of candidates for an implantable defibrillator. Europace 9: Huikuri, HV, MJ Raatikainen, R Moerch-Joergensen et al Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction. Eur. Heart J. 30: Gatzoulis, KA, D Tsiachris, P Arsenos et al Prognostic value of programmed ventricular stimulation for sudden death in selected high risk patients with structural heart disease and preserved systolic function. Int. J. Cardiol. 176: Moss, AJ, WJ Hall, DS Cannom et al Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. multicenter automatic defibrillator implantation trial investigators. N. Engl. J. Med. 335: Buxton, AE, KL Lee, JD Fisher et al A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter unsustained tachycardia trial investigators. N. Engl. JMed. 341: Daubert, JP, W Zareba, WJ Hall et al Predictive value of ventricular arrhythmia inducibility for subsequent ventricular tachycardia or ventricular fibrillation in multicenter automatic defibrillator implantation Trial (MADIT) II patients. J. Am. Coll. Cardiol. 47: Gatzoulis, KA, D Tsiachris, P Arsenos, and D Tousoulis Electrophysiologic testing guided risk stratification approach for sudden cardiac death beyond the left ventricular ejection fraction. World J. Cardiol. 8(1): Moss, AJ, W Zareba, WJ Hall et al Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N. Engl. J. Med. 346: Bardy, GH, KL Lee, DB Mark et al Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N. Engl. J. Med. 352: Ikeda, T, T Sakata, M Takami et al Combined assessment of T-wave alternans and late potentials used to predict arrhythmic events after myocardial infarction. A prospective study. J. Am. Coll. Cardiol. 35: Exner, DV, KM Kavanagh, MP Slawnych et al Noninvasive risk assessment early after a myocardial infarction the REFINE study. J. Am. Coll. Cardiol. 50: Ikeda, T, H Yoshino, K Sugi et al Predictive value of microvolt T-wave alternans for sudden cardiac death in patients with preserved cardiac function after acute myocardial infarction. J. Am. Coll. Cardiol. 48: Bauer, A, P Barthel, R Schneider et al Improved stratification of autonomic regulation for risk prediction in postinfarction patients with preserved left ventricular function (ISAR-Risk). Eur. Heart J. 30: Steinbeck, G, D Andresen, K Seidl et al Defibrillator implantation early after myocardial infarction. N. Engl. J. Med. 361(15): Hohnloser, SH, KH Kuck, P Dorian et al Prophylactic use of an implantable cardioverterdefibrillator after acute myocardial infarction. New Engl J Med 351(24): Silvia, G, SG Priori, C Blomstr om-lundqvist et al ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur. Heart J. 36: Australian New Zealand Clinical Trial Registry: Available at [ACTRN ]. 30. ClinicalTrials.gov Identifier: NCT Efficacy of Implantable Defibrillator Therapy After a Myocardial Continuing Cardiology Education, doi: /cce2.33 (149 of 150)
7 Risk Stratification for Sudden Cardiac Death in Post-infarction Patients P. Arsenos et al. Infarction (REFINE-ICD). Available at www. clinicaltrials.gov. 31. ClinicalTrials.gov Identifier: NCT Cardiac Magnetic Resonance GUIDEd Management of Mild to moderate Left Ventricular Systolic Dysfunction trial. (CMR GUIDE). Available at www. clinicaltrials.gov. 32. ClinicalTrials.gov Identifier: NCT The Risk Stratification in Patients With Preserved Ejection Fraction trial (PRESERVE EF) Available at www. clinicaltrials.gov. 33. Gatzoulis, KA, D Tsiachris, P Arsenos et al Post myocardial infarction risk stratification for sudden cardiac death in patients with preserved ejection fraction: PRESERVE-EF Study design. Hellenic J. Cardiol. 55: Continuing Cardiology Education, doi: /cce2.33 (150 of 150)
20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney disease CKD Brugada 5 Brugada Brugada 1
Symposium 39 45 1 1 2005 2008 108000 59000 55 1 3 0.045 1 1 90 95 5 10 60 30 Brugada 5 Brugada 80 15 Brugada 1 80 20 2 12 X 2 1 1 brain natriuretic peptide BNP 20 ng/ml 200 ng/ml 1000 ng/ml chronic kidney
More informationImplantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure
Implantable Cardioverter Defibrillator Therapy in MADIT II Patients with Signs and Symptoms of Heart Failure Wojciech Zareba Postinfarction patients with left ventricular dysfunction are at increased risk
More informationArrhythmias Focused Review. Who Needs An ICD?
Who Needs An ICD? Cesar Alberte, MD, Douglas P. Zipes, MD, Krannert Institute of Cardiology, Indiana University School of Medicine, Indianapolis, IN Sudden cardiac arrest is one of the most common causes
More informationICD. Guidelines and Critical Review of Trials. Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011
ICD Guidelines and Critical Review of Trials Win K. Shen, MD Professor of Medicine Mayo Clinic College of Medicine Mayo Clinic Arizona Torino 2011 Disclosure Relevant Financial Relationship(s) None Off
More informationMEDICAL POLICY SUBJECT: MICROVOLT T-WAVE ALTERNANS
MEDICAL POLICY PAGE: 1 OF: 6 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.
More informationWhat Every Physician Should Know:
What Every Physician Should Know: The Canadian Heart Rhythm Society estimates that, in Canada, sudden cardiac death (SCD) is responsible for about 40,000 deaths annually; more than AIDS, breast cancer
More informationVentricular Tachycardia Ablation. Saverio Iacopino, MD, FACC, FESC
Ventricular Tachycardia Ablation Saverio Iacopino, MD, FACC, FESC ü Ventricular arrhythmias, both symptomatic and asymptomatic, are common, but syncope and SCD are infrequent initial manifestations of
More informationΠρόληψη του ΑΚΘ σε ασθενείς με μη-ισχαιμική μυοκαρδιοπάθεια:
Πρόληψη του ΑΚΘ σε ασθενείς με μη-ισχαιμική μυοκαρδιοπάθεια: Νεώτερα δεδομένα στη διαστρωμάτωση κινδύνου Εμμ. Μ. Κανουπάκης MD, PhD, FESC Πανεπιστημιακό Νοσοκομείο Ηρακλείου NIDCM Presence of LV dilatation
More informationROLE OF THE SIGNAL ECG IN RISK STRATIFICATION OF SCD. An overview
ROLE OF THE SIGNAL ECG IN RISK STRATIFICATION OF SCD. An overview Nabil El-Sherif, MD SUNY - Downstate Medical Center & New York harbor VA Healthcare System Brooklyn, NY, USA Signal Averaged ECG: A Selective
More informationNoninvasive Predictors of Sudden Cardiac Death
2011 년순환기관련학회춘계통합학술대회 Noninvasive Predictors of Sudden Cardiac Death 영남대학교의과대학순환기내과학교실신동구 Diseases associated with SCD Previous SCD event Prior episode of ventricular tachyarrhythmia Previous myocardial
More informationSudden death as co-morbidity in patients following vascular intervention
Sudden death as co-morbidity in patients following vascular intervention Impact of ICD therapy Seah Nisam Director, Medical Science, Guidant Corporation Advanced Angioplasty Meeting (BCIS) London, 16 Jan,
More informationT-Wave Alternans. Policy # Original Effective Date: 06/05/2002 Current Effective Date: 09/17/2014
Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc.(collectively referred to as the Company ), unless otherwise provided
More informationPrevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias
Prevention of sudden cardiac death: With an emphasis on sudden cardiac death from ventricular arrhythmias The Toronto ACS Summit Toronto, March 1, 2014 Andrew C.T. Ha, MD, MSc, FRCPC Cardiac Electrophysiology
More information03/17/16, 03/16/17, 03/15/18 CATEGORY: Technology Assessment. Proprietary Information of Excellus Health Plan, Inc.
MEDICAL POLICY SUBJECT: MICROVOLT T-WAVE ALTERNANS, PAGE: 1 OF: 6 If a product excludes coverage for a service, it is not covered, and medical policy criteria do not apply. If a commercial product, including
More informationSignal-Averaged Electrocardiography (SAECG)
Medical Policy Manual Medicine, Policy No. 21 Signal-Averaged Electrocardiography (SAECG) Next Review: April 2018 Last Review: April 2017 Effective: May 1, 2017 IMPORTANT REMINDER Medical Policies are
More informationSummary, conclusions and future perspectives
Summary, conclusions and future perspectives Summary The general introduction (Chapter 1) of this thesis describes aspects of sudden cardiac death (SCD), ventricular arrhythmias, substrates for ventricular
More informationSUDDEN CARDIAC DEATH(SCD): Definition
SUDDEN CARDIAC DEATH EPIDEMIOLOGY, PATHOPHYSIOLOGY, PREVENTION & THERAPY Hasan Garan, M.D. Columbia University Medical Center SUDDEN CARDIAC DEATH(SCD): Definition DEATH DUE TO A CARDIAC CAUSE IN A CLINICALLY
More informationSUDDEN CARDIAC DEATH(SCD): Definition
SUDDEN CARDIAC DEATH EPIDEMIOLOGY, PATHOPHYSIOLOGY, PREVENTION & THERAPY Hasan Garan, M.D. Columbia University Medical Center SUDDEN CARDIAC DEATH(SCD): Definition DEATH DUE TO A CARDIAC CAUSE IN A CLINICALLY
More informationPublic Statement: Medical Policy Statement:
Medical Policy Title: Cardioverter- ARBenefits Approval: 09/7/2011 Defibrillators Effective Date: 01/01/2012 Document: ARB0096 Revision Date: Code(s): C1721, C1722, C1777, C1882, C1895, C1896 and C1899
More informationRisk Stratification of Sudden Cardiac Death
Risk Stratification of Sudden Cardiac Death Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: None Sudden Cardiac Death A Major Public Health Problem > 1/2 of
More informationPrimary prevention of SCD with the ICD in Nonischemic Cardiomyopathy
Primary prevention of SCD with the ICD in Nonischemic Cardiomyopathy Michael R Gold, MD, PhD Medical University of South Carolina Charleston, SC USA Disclosures: Consulting and Clinical Trials Medtronic
More informationAntiarrhythmic Drugs and Ablation in Patients with ICD and Shocks
Antiarrhythmic Drugs and Ablation in Patients with ICD and Shocks Alireza Ghorbani Sharif, MD Interventional Electrophysiologist Tehran Arrhythmia Clinic January 2016 Recurrent ICD shocks are associated
More informationPreventing Sudden Death Current & Future Role of ICD Therapy
Preventing Sudden Death Current & Future Role of ICD Therapy Derek V Exner, MD, MPH, FRCPC, FACC, FAHA, FHRS Professor, Libin Cardiovascular Institute of Alberta Canada Research Chair, Cardiovascular Clinical
More informationSudden Cardiac Death What an electrophysiologist thinks a cardiologist should know
Sudden Cardiac Death What an electrophysiologist thinks a cardiologist should know Steven J. Kalbfleisch, M.D. Medical Director Electrophysiology Laboratory Ross Heart Hospital Wexner Medical Center Sudden
More informationMEDICAL POLICY POLICY TITLE T-WAVE ALTERNANS TESTING POLICY NUMBER MP
Original Issue Date (Created): August 23, 2002 Most Recent Review Date (Revised): September 24, 2013 Effective Date: November 1, 2013 I. POLICY T-wave alternans is considered investigational as a technique
More informationWho does not need a primary preventive ICD?
Who does not need a primary preventive ICD? Hildegard Tanner, Bern Universitätsklinik für Kardiologie Disclosure of potential conflicts of interest Travel grants for educational purposes from: Biosense
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: signal_averaged_ecg 7/1992 10/2017 10/2018 10/2017 Description of Procedure or Service Signal-averaged electrocardiography
More informationMichel Mirowski and colleagues ABSTRACT CARDIOLOGY. ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death
ICD Update: New Evidence and Emerging Clinical Roles in Primary Prevention of Sudden Cardiac Death Ronald D. Berger, MD, PhD, FACC ABSTRACT PURPOSE: To review recent major randomized trials of implantable
More informationDo All Patients With An ICD Indication Need A BiV Pacing Device?
Do All Patients With An ICD Indication Need A BiV Pacing Device? Muhammad A. Hammouda, MD Electrophysiology Laboratory Department of Critical Care Medicine Cairo University Etiology and Pathophysiology
More informationPrevention of Sudden Death in ARVC
ESC Munich, August 29, 2012 Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC): Prevention of Sudden Death in ARVC Thomas Wichter, MD, FESC Professor of Medicine - Cardiology Marienhospital Osnabrück
More informationPrimary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life
Chapter 3 Primary prevention ICD recipients: the need for defibrillator back-up after an event-free first battery service-life Guido H. van Welsenes, MS, Johannes B. van Rees, MD, Joep Thijssen, MD, Serge
More informationESC Stockholm Arrhythmias & pacing
ESC Stockholm 2010 Take Home Messages for Practitioners Arrhythmias & pacing Prof. Panos E. Vardas Professor of Cardiology Heraklion University Hospital Crete, Greece Disclosures Small teaching fees from
More informationTachycardia Devices Indications and Basic Trouble Shooting
Tachycardia Devices Indications and Basic Trouble Shooting Peter A. Brady, MD., FRCP Cardiology Review Course London, March 6 th, 2014 2011 MFMER 3134946-1 Tachycardia Devices ICD Indications Primary and
More informationAutomatic External Defibrillators
Last Review Date: April 21, 2017 Number: MG.MM.DM.10dC3v4 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationICD in a young patient with syncope
ICD in a young patient with syncope Konstantinos P. Letsas, MD, FESC Second Department of Cardiology Evangelismos General Hospital of Athens Athens, Greece Case presentation A 17-year-old apparently healthy
More informationThe Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia
The Therapeutic Role of the Implantable Cardioverter Defibrillator in Arrhythmogenic Right Ventricular Dysplasia By Sandeep Joshi, MD and Jonathan S. Steinberg, MD Arrhythmia Service, Division of Cardiology
More informationSeveral studies of the primary prevention. Original Research
Original Research Hellenic J Cardiol 2015; 56: 230-236 Inducibility of Ventricular Arrhythmia and Tachyarrhythmia Recurrences in Patients with Implantable Defibrillator Giuseppe Stabile 1, Paolo Gallo
More informationEXPERT CONSENSUS DOCUMENT
EXPERT CONSENSUS DOCUMENT American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying Patients
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure (review
More informationAtrial fibrillation (AF) is a disorder seen
This Just In... An Update on Arrhythmia What do recent studies reveal about arrhythmia? In this article, the authors provide an update on atrial fibrillation and ventricular arrhythmia. Beth L. Abramson,
More informationThe patient with electric storm
The complex patient in the cardiac care unit: The patient with electric storm Helmut U. Klein University of Rochester Medical Center Heart Research Follow-up Program and Isar Heart Center Muenchen Presenter
More informationIHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT JANUARY 24, 2012
IHCP bulletin INDIANA HEALTH COVERAGE PROGRAMS BT201203 JANUARY 24, 2012 The IHCP to reimburse implantable cardioverter defibrillators separately from outpatient implantation Effective March 1, 2012, the
More informationICD Therapy. Disclaimers
ICD Therapy Rodney Horton, MD Texas Cardiac Arrhythmia Institute Texas Cardiovascular, PA Austin, TX Speaker s Bureau St. Jude Medical Medtronic Boston Scientific Disclaimers Clinical Advisory Panel St.
More informationThe implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease
The implantable cardioverter defibrillator is not enough: Ventricular Tachycardia Catheter Ablation in Patients with Structural Heart Disease Paolo Della Bella, MD Arrhythmia Department and Clinical Electrophysiology
More informationThe International Classification of Diseases, Tenth Revision,
AHA/ACCF/HRS Scientific Statement American Heart Association/American College of Cardiology Foundation/Heart Rhythm Society Scientific Statement on Noninvasive Risk Stratification Techniques for Identifying
More informationSynopsis of Management on Ventricular arrhythmias. M. Soni MD Interventional Cardiologist
Synopsis of Management on Ventricular arrhythmias M. Soni MD Interventional Cardiologist No financial disclosure Premature Ventricular Contraction (PVC) Ventricular Bigeminy Ventricular Trigeminy Multifocal
More information/$ -see front matter 2011 Heart Rhythm Society. All rights reserved. doi: /j.hrthm
Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial
More informationRecurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm
Recurrent Implantable Defibrillator Discharges (ICD) Discharges ICD Storm Guy Amit, MD, MPH Soroka University Medical Center Ben-Gurion University of the Negev Beer-Sheva, Israel Disclosures Consultant:
More informationVentricular arrhythmias in acute coronary syndromes. Dimitrios Manolatos, MD, PhD, FESC Electrophysiology Lab Evaggelismos General Hospital
Ventricular arrhythmias in acute coronary syndromes Dimitrios Manolatos, MD, PhD, FESC Electrophysiology Lab Evaggelismos General Hospital introduction myocardial ischaemia and infarction leads to severe
More informationDefibrillation threshold testing should no longer be performed: contra
Defibrillation threshold testing should no longer be performed: contra Andreas Goette St. Vincenz-Hospital Paderborn Dept. of Cardiology and Intensive Care Medicine Germany No conflict of interest to disclose
More informationTitle: Automatic External Defibrillators Division: Medical Management Department: Utilization Management
Retired Date: Page 1 of 7 1. POLICY DESCRIPTION: Automatic External Defibrillators 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy,
More informationArrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh
Arrhythmias and Heart Failure Dr Chris Lang Consultant Cardiologist and Electrophysiologist Royal Infirmary of Edinburgh Arrhythmias and Heart Failure Ventricular Supraventricular VT/VF Primary prevention
More informationProphylactic ablation
Ventricular tachycardia in ischaemic heart disease. Update on electrical therapy 29 august 2010 Prophylactic ablation Pasquale Notarstefano Cardiovacular Department S. Donato Hospital, Arezzo (IT) Prophylactic
More informationSudden cardiac death. (Heart Rhythm 2010;7: ) 2010 Heart Rhythm Society. All rights reserved.
Gender differences in clinical outcome and primary prevention defibrillator benefit in patients with severe left ventricular dysfunction: A systematic review and meta-analysis Pasquale Santangeli, MD,*
More informationRe: National Coverage Analysis (NCA) for Implantable Cardioverter Defibrillators (CAG R4)
December 20, 2017 Ms. Tamara Syrek-Jensen Director, Coverage & Analysis Group Centers for Medicare & Medicaid Services 7500 Security Boulevard Baltimore, MD 21244 Re: National Coverage Analysis (NCA) for
More informationTachycardias II. Štěpán Havránek
Tachycardias II Štěpán Havránek Summary 1) Supraventricular (supraventricular rhythms) Atrial fibrillation and flutter Atrial ectopic tachycardia / extrabeats AV nodal reentrant a AV reentrant tachycardia
More informationJournal of the American College of Cardiology Vol. 41, No. 12, by the American College of Cardiology Foundation ISSN /03/$30.
Journal of the American College of Cardiology Vol. 41, No. 12, 2003 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00 Published by Elsevier Inc. doi:10.1016/s0735-1097(03)00467-4
More informationCRT-P or CRT-D From North Alberta to Nairobi
CRT-P or CRT-D From North Alberta to Nairobi Dr Mzee Ngunga Aga Khan University Hospital Nairobi KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web:
More informationJournal of the American College of Cardiology Vol. 44, No. 7, by the American College of Cardiology Foundation ISSN /04/$30.
Journal of the American College of Cardiology Vol. 44, No. 7, 2004 2004 by the American College of Cardiology Foundation ISSN 0735-1097/04/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2004.06.063
More informationQRS Duration Does Not Predict Occurrence of Ventricular Tachyarrhythmias in Patients With Implanted Cardioverter-Defibrillators
Journal of the American College of Cardiology Vol. 46, No. 2, 2005 2005 by the American College of Cardiology Foundation ISSN 0735-1097/05/$30.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.03.060
More informationThe Multicenter Unsustained Tachycardia Trial (MUSTT)
Effect of Implantable Defibrillators on Arrhythmic Events and Mortality in the Multicenter Unsustained Tachycardia Trial Kerry L. Lee, PhD; Gail Hafley, MS; John D. Fisher, MD; Michael R. Gold, MD; Eric
More informationMicrovolt T-Wave Alternans and the Risk of Death or Sustained Ventricular Arrhythmias in Patients With Left Ventricular Dysfunction
Journal of the American College of Cardiology Vol. 47, No. 2, 2006 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2005.11.026
More informationNovel Approaches to VT Management Glenn M Polin MD
Novel Approaches to VT Management Glenn M Polin MD Medical Director, Electrophysiology Laboratory John Ochsner Heart and Vascular Institute New Orleans, LA Disclosures Pfizer Speaker Bureau Bristol Myers
More informationClinical Policy: Microvolt T-Wave Alternans Testing Reference Number: CP.MP.212
Clinical Policy: Reference Number: CP.MP.212 Effective Date: 03/05 Last Review Date: 09/17 See Important Reminder at the end of this policy for important regulatory and legal information. Coding Implications
More informationCME Article Brugada pattern masking anterior myocardial infarction
Electrocardiography Series Singapore Med J 2011; 52(9) : 647 CME Article Brugada pattern masking anterior myocardial infarction Seow S C, Omar A R, Hong E C T Cardiology Department, National University
More informationORIGINAL INVESTIGATION
ORIGINAL INVESTIGATION Effectiveness of Implantable Cardioverter-Defibrillators in Patients With Ischemic Heart Disease and Left Ventricular Dysfunction Paul S. Chan, MD, MSc; Theodore Chow, MD; Dean Kereiakes,
More informationComparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart failure
HOT TOPIC Cardiology Journal 2010, Vol. 17, No. 6, pp. 543 548 Copyright 2010 Via Medica ISSN 1897 5593 Comparison of clinical trials evaluating cardiac resynchronization therapy in mild to moderate heart
More informationResponse of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT
Response of Right Ventricular Size to Treatment with Cardiac Resynchronization Therapy and the Risk of Ventricular Tachyarrhythmias in MADIT-CRT Heart Rhythm Society (May 11, 2012) Colin L. Doyle, BA,*
More informationThe Immediate Reproducibility of T Wave Alternans During Bicycle Exercise
Reprinted with permission from JOURNAL OF PACING AND CLINICAL ELECTROPHYSIOLOGY, Volume 25, No. 8, August 2002 Copyright 2002 by Futura Publishing Company, Inc., Armonk, NY 10504-0418. The Immediate Reproducibility
More informationJean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F
SECONDARY PREVENTION of Sudden Death: in which patients? Jean François Leclercq Department of Rythmology Private Hospital of Parly 2 - Le Chesnay F Why an AID is effective? Because it stoppes a VT very
More informationSecondary prevention of sudden cardiac death
Secondary prevention of sudden cardiac death Balbir Singh, MD, DM; Lakshmi N. Kottu, MBBS, Dip Card, PGPCard Department of Cardiology, Medanta Medcity Hospital, Gurgaon, India Abstract All randomised secondary
More informationPolypharmacy - arrhythmic risks in patients with heart failure
Influencing sudden cardiac death by pharmacotherapy Polypharmacy - arrhythmic risks in patients with heart failure Professor Dan Atar Head, Dept. of Cardiology Oslo University Hospital Ullevål Norway 27.8.2012
More informationΕκθορηίζεις απινιδωηή και θνηηόηηηα: μέθοδοι μείωζης ηων θεραπειών απινίδωζης
Εκθορηίζεις απινιδωηή και θνηηόηηηα: μέθοδοι μείωζης ηων θεραπειών απινίδωζης Εμμ. Μ. Κανοσπάκης Καρδιολογική Κλινική Πανεπιζηημίοσ Κρήηης Lessons from large trials Conditioning Rhythm and Electrical Therapy
More informationIntroduction. CLINICAL RESEARCH Clinical Trial Design. Mohammad Saeed 1 *, Mehdi Razavi 1, Curtis G. Neason 2, and Simona Petrutiu 2. Aims.
Europace (2011) 13, 1648 1652 doi:10.1093/europace/eur195 CLINICAL RESEARCH Clinical Trial Design Rationale and design for programming implantable cardioverter defibrillators in patients with primary prevention
More informationOriginal Article Fragmented QRS as a Predictor of Appropriate Implantable Cardioverter-defibrillator Therapy
4 Original Article Fragmented QRS as a Predictor of Appropriate Implantable Cardioverter-defibrillator Therapy Sirin Apiyasawat, Dujdao Sahasthas, Tachapong Ngarmukos, Pakorn Chandanamattha, Khanchit Likittanasombat
More informationSudden cardiac death: Primary and secondary prevention
Sudden cardiac death: Primary and secondary prevention By Kai Chi Chan Penultimate Year Medical Student St George s University of London at UNic Sheba Medical Centre Definition Sudden cardiac arrest (SCA)
More informationWhere Does the Wearable Cardioverter Defibrillator (WCD) Fit In?
Where Does the Wearable Cardioverter Defibrillator (WCD) Fit In? 24 th Annual San Diego Heart Failure Symposium June 1-2, 2018 La Jolla, CA Barry Greenberg, MD Distinguished Professor of Medicine Director,
More informationDeclaration of conflict of interest. None to declare
Declaration of conflict of interest None to declare Risk management of coronary artery disease Arrhythmias and diabetes Hercules Mavrakis Cardiology Department Heraklion University Hospital Crete, Greece
More informationThe Role of ICD Therapy in Cardiac Resynchronization
The Role of ICD Therapy in Cardiac Resynchronization The Korean Society of Circulation 15 April 2005 Angel R. León, MD Carlyle Fraser Heart Center Division of Cardiology Emory University School of Medicine
More informationIntroduction. CLINICAL RESEARCH Sudden death and ICDs
Europace (14) 16, 1315 1321 doi:.93/europace/euu26 CLINICAL RESEARCH Sudden death and ICDs What is the optimal left ventricular ejection fraction cut-off for risk stratification for primary prevention
More informationICD THERAPIES: are they harmful or just high risk markers?
ICD THERAPIES: are they harmful or just high risk markers? Konstantinos P. Letsas, MD, PhD, FESC LAB OF CARDIAC ELECTROPHYSIOLOGY EVANGELISMOS GENERAL HOSPITAL ATHENS ICD therapies are common In a meta-analysis
More informationNon-invasive sudden death risk stratification
Non-invasive sudden death risk stratification Roberto F.E. Pedretti, Simona Sarzi Braga Division of Cardiology, IRCCS S. Maugeri Foundation, Scientific Institute of Tradate, Tradate (VA), Italy Key words:
More informationSilvia G Priori MD PhD
The approach to the cardiac arrest survivor Silvia G Priori MD PhD Molecular Cardiology, IRCCS Fondazione Salvatore Maugeri Pavia, Italy AND Leon Charney Division of Cardiology, Cardiovascular Genetics
More informationPause-induced Ventricular Tachycardia: Clinical Characteristics
Pause-induced Ventricular Tachycardia: Clinical Characteristics Margaret Bond A. Study Purpose and Rationale Until three decades ago, ventricular arrhythmias were thought to be rare in occurrence and their
More informationSyncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France
Syncope in Heart Failure Patients How to judge and treat? Jean-Claude Deharo, MD, FESC Marseilles, France Syncope in advanced heart failure: high risk of sudden death N = 491 patients with HF (NYHA III-IV)
More informationThe concept of the implantable cardioverter-defibrillator (ICD) was introduced
Review Rohit Kedia, MD Mohammad Saeed, MD, FACC Implantable Cardioverter-Defibrillators Indications and Unresolved Issues Since the implantable cardioverter-defibrillator was first used clinically in 1980,
More informationVentricular tachycardia and ischemia. Martin Jan Schalij Department of Cardiology Leiden University Medical Center
Ventricular tachycardia and ischemia Martin Jan Schalij Department of Cardiology Leiden University Medical Center Disclosure: Research grants from: Boston Scientific Medtronic Biotronik Sudden Cardiac
More informationHeart failure and sudden death
Heart failure and sudden death What did we learn so far from important ICD- and CRT trials? Helmut U. Klein M.D. University of Rochester Medical Center Heart Research Follow up Program Arrhythmic substrate
More informationThe Italian Implantable Cardioverter- Defibrillator Registry. A survey of the national activity during the years
The Italian Implantable Cardioverter- Defibrillator Registry. A survey of the national activity during the years 2001-2003 Alessandro Proclemer, Marco Ghidina*, Gloria Cicuttini*, Dario Gregori*, Paolo
More informationHeart Rhythm Disorders. How do you quantify risk?
Heart Rhythm Disorders How do you quantify risk? Heart Rhythm Disorders Scale of the Problem 1/2 population will have an episode of transient loss of consciousness (T-LOC) at some stage in their life.
More information4/14/15. The Electrocardiogram. In jeopardy more than a century after its introduction by Willem Einthoven? Time for a revival. by Hein J.
The Electrocardiogram. In jeopardy more than a century after its introduction by Willem Einthoven? Time for a revival. by Hein J. Wellens MD 1 Einthoven, 1905 The ECG! Everywhere available! Easy and rapid
More informationMicrovolt T-Wave Alternans for Risk Stratification in Athletes with Ventricular Arrhythmias: Correlation with Programmed Ventricular Stimulation
Microvolt T-Wave Alternans for Risk Stratification in Athletes with Ventricular Arrhythmias: Correlation with Programmed Ventricular Stimulation Giuseppe Inama, M.D., Claudio Pedrinazzi, M.D., Ornella
More informationAre there low risk patients in Brugada syndrome?
Are there low risk patients in Brugada syndrome? Pedro Brugada MD, PhD Andrea Sarkozy MD Risk stratification in Brugada syndrome In the last years risk stratification in Brugada syndrome has become the
More informationTHE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA
THE ROLE OF ICD THERAPY FOR PRIMARY PREVENTION Leonard Ganz, M.D. Pittsburgh, PA Speakers Bureau: Zoll / Lifecore, Sanofi Aventis, Cardionet Consultant: Boston Scientific, St. Jude Medical, Biotronik,
More informationNon-Invasive Ablation of Ventricular Tachycardia
Non-Invasive Ablation of Ventricular Tachycardia Dr Shaemala Anpalakhan Newcastle upon Tyne Hospitals NHS Foundation Trust Freeman Road, Newcastle Upon Tyne, NE7 7DN Contact: shaemala@doctors.org.uk Introduction
More informationShocks burden and increased mortality in implantable cardioverter-defibrillator patients
Shocks burden and increased mortality in implantable cardioverter-defibrillator patients Gail K. Larsen, MD, MPH,* John Evans, MD, William E. Lambert, PhD,* Yiyi Chen, PhD,* Merritt H. Raitt, MD* From
More informationManagement of patients with ventricular tachycardia in Europe: results of the European Heart Rhythm Association survey
Europace (2015) 17, 1294 1299 doi:10.1093/europace/euv255 EP WIRE Management of patients with ventricular tachycardia in Europe: results of the European Heart Rhythm Association survey Jian Chen 1 *, Derick
More informationShock Reduction Strategies Michael Geist E. Wolfson MC
Shock Reduction Strategies Michael Geist E. Wolfson MC Shock Therapy Thanks, I needed that! Why Do We Need To Reduce Shocks Long-term outcome after ICD and CRT implantation and influence of remote device
More information2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline. Top Ten Messages. Eleftherios M Kallergis, MD, PhD, FESC
2017 AHA/ACC/HRS Ventricular Arrhythmias and Sudden Cardiac Death Guideline Top Ten Messages Eleftherios M Kallergis, MD, PhD, FESC Cadiology Department - Heraklion University Hospital No actual or potential
More informationImpact of Shocks on Mortality in Patients with Ischemic or Dilated Cardiomyopathy and Defibrillators Implanted for Primary Prevention
Impact of Shocks on Mortality in Patients with Ischemic or Dilated Cardiomyopathy and Defibrillators Implanted for Primary Prevention Florian Streitner*, Thomas Herrmann, Juergen Kuschyk, Siegfried Lang,
More information